New inhaled drug aims to slow lung transplant rejection
Disease control
Recruiting now
This study tests an inhaled drug called LAM-001 in 30 lung transplant patients who have developed chronic rejection (BOS). Participants will inhale LAM-001 or a placebo daily for 48 weeks. Researchers will check if the drug is safe and can slow the decline in lung function.
Phase: PHASE2 • Sponsor: Steven Hays, MD • Aim: Disease control
Last updated May 17, 2026 05:08 UTC